Adagene Inc. (ADAG) News
Filter ADAG News Items
ADAG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ADAG News From Around the Web
Below are the latest news stories about ADAGENE INC that investors may wish to consider to help them evaluate ADAG as an investment opportunity.
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023- MSS CRC case examples reinforce optimal dosing regimen in ongoing phase 2 dose expansion, with a confirmed partial response at ADG126 10 mg/kg every three weeks plus pembrolizumab – - Integrated pharmacokinetic and clinical data analyses support the mechanism of action for ADG126 and its profile as a potential best-in-class CTLA-4 therapy across tumor types - SAN DIEGO and SUZHOU, China, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the disco |
Are Medical Stocks Lagging Boston Scientific (BSX) This Year?Here is how Boston Scientific (BSX) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Are Medical Stocks Lagging Medpace (MEDP) This Year?Here is how Medpace (MEDP) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year. |
Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody® ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting- Data reinforces mechanism of action and selection of 10 mg/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort – SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego. Details for the poster i |
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year. |
Potential Upside For Adagene Inc. (NASDAQ:ADAG) Not Without RiskAdagene Inc.'s ( NASDAQ:ADAG ) price-to-sales (or "P/S") ratio of 2.8x might make it look like a strong buy right now... |
Adagene to Present at Investor and Scientific Conferences in SeptemberAdagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the company's participation in several upcoming investor and scientific conferences. |
Are Medical Stocks Lagging Adagene (ADAG) This Year?Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year. |
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update- Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy – - Strong efficacy signal observed in MSS CRC phase 2 single arm study for SAFEbody® ADG126 in combination with pembrolizumab at the 10 mg/kg every three weeks dosing regimen - - Advancing MSS CRC cohort with ten more patients at the active every three weeks dosing regimen for SAFEbody ADG126 plus pembr |
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?Here is how Adagene Inc. Sponsored ADR (ADAG) and The Cooper Companies (COO) have performed compared to their sector so far this year. |